Study Condition(s): Advanced Cancer, Metastatic Cancer, Colorectal Cancer, Non-small Cell Lung Cancer

A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer

Study Alias: JTJL

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT02860780 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The main purpose of this study is to evaluate the safety of the study drug prexasertib in combination with ralimetinib in participants with advanced or metastatic cancer.

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria

Gender

Male Female

Age

18+ years

Time Commitment

Your participation may continue for as long as you and your study doctor feel that you are benefiting from the study treatment.
  • Participant must have advanced or metastatic cancer and be able to swallow tablets
  • Participant must have discontinued all previous treatments for cancer and recovered from the acute effects from the therapy
  • Participant must not have an active infection (fungal, viral, or bacterial)
  • Participant must not have active cancer in your brain or spinal cord
  • Participant must not have acute or chronic leukemia
  • Participant must not have a diagnosis of inflammatory bowel disease
  • Participant must not have had major small bowel resection
  • Participant must not be in other clinical trials investigating prexasertib or ralimetinib
  • Female participant must not be pregnant or breastfeeding

Where to Participate

7 locations are currently available of 7 planned
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.